Journals / Eurasian Journal of Medicine / 2016 / Cilt: 48 - Sayı: 3

Endometrium ve Over Kanserinde MR Görüntüleme ile Serum HE-4 ve CA 125 Düzeylerinin Hastalığın Yaygınlığını Değerlendirmedeki Önemi

Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation

Pages
192–198
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Peripheral blood samples were taken and serum CA 125 and HE-4 were tested.Results: Serum CA 125 and HE-4 levels in patients with ovarian cancer were found to be significantly higher than those in healthy volunteers (p0.05), whereas HE-4 levels were found to be higher in patients with endometrial cancer than in healthy controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Currently, no clinically useful tumor marker is available for primary diagnosis in endometrial cancer.
📊
Key Findings & Data:Human epididymis protein-4 (HE-4) has high sensitivity and specificity as a tumor marker.
💡
Conclusion & Impact:Peripheral blood samples were taken and serum CA 125 and HE-4 were tested.Results: Serum CA 125 and HE-4 levels in patients with ovarian cancer were found to be significantly higher than those in healthy volunteers (p0.05), whereas HE-4 levels were found to be higher in patients with endometrial cancer than in healthy controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Currently, no clinically useful tumor marker is available for primary diagnosis in endometrial cancer. Human epididymis protein-4 (HE-4) has high sensitivity and specificity as a tumor marker. Further, HE-4 has been shown to be elevated in early stage endometrial cancer and is more sensitive than CA 125. In our study, CA 125 and HE-4 reputation as a tumor marker for diagnosis of ovarian and endometrial cancer with the use of both the availability and affect the way we investigated the rate of diagnosis.Materials and Methods: Here 20 patients with ovarian cancer, 26 patients with endometrial cancer, which had been histologically diagnosed, and 40 healthy volunteers were included. Peripheral blood samples were taken and serum CA 125 and HE-4 were tested.Results: Serum CA 125 and HE-4 levels in patients with ovarian cancer were found to be significantly higher than those in healthy volunteers (p0.05), whereas HE-4 levels were found to be higher in patients with endometrial cancer than in healthy controls (p

Özet

Amaç: CA 125 erken evre over kanserlerinin sadece %50'sinde yükselir. Endometrium kanserinde klinik pratikte rutin olarak kullanılan tümör marker yoktur. Human epididimis protein-4 (HE-4) over kanserlerinde yüksek sensitivite ve spesifiteye sahiptir. Endometrial kanserde CA 125 den daha sensitif olduğu ve erken evrede yükseldiği gösterilmiştir. Çalışmamızda CA 125 ve HE-4'ün over ve endometrium kanserinde tümör markerı olarak kullanılabilirliğini ve ikisinin birlikte kullanımın teşhis oranını ne şekilde etkileyeceğini araştırdık.Gereç ve Yöntem: Çalışmamıza histopatolojik olarak tanısı konulan 20 over kanseri, 26 endometrium kanseri hasta ile jinekolojik problemi olmayan 40 sağlıklı gönüllü dahil edilmiştir. MR görüntülemesiyle FIGO sistemine göre evreleri belirlendi. Hastalardan preoperatif olarak ve sağlıklı gönüllülerden periferik kan alınarak serum CA 125 ve HE-4 düzeyleri çalışıldı.Bulgular: Over kanseri hastalarının serum CA 125 ve HE-4 düzeyleri sağlıklı kontrollerinkinden anlamlı yüksek bulundu (p0,05), HE-4 düzeyleri yüksek bulunmuştur (p

🔖

Cite This Article

YILMAZ, E. P. T., KUMTEPE, Y. (2022). Endometrium ve Over Kanserinde MR Görüntüleme ile Serum HE-4 ve CA 125 Düzeylerinin Hastalığın Yaygınlığını Değerlendirmedeki Önemi. Eurasian Journal of Medicine, Cilt: 48 - Sayı: 3, 192–198. https://ajindex.com/articles/509055

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009; 9: 555-66. [CrossRef] Zacharakis D, Thomakos N, Biliatis I, et al. Ultrasonographic markers and preoperative CA-125 to distinguish between borderline ovarian tumors and stage I ovarian cancer. Acta Obstet Gynecol Scand 2013; 92: 285-92. [CrossRef] Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol 2008; 66: 10-20. [CrossRef] Farias-Eisner G, Su F, Robbins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer. Am J Obstet Gynecol 2010; 202: 73. [CrossRef] Changes in definition of clinical staging for carci- noma of the cervix and ovary. Am J Obstet Gynecol 1987; 156: 236. Tsikouras P, Bouchlariotou S, Vrachnis N, et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol 2013; 169: 1-9. [CrossRef] Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105: 103-4. [CrossRef] Tessitore A, Gaggiano A, Cicciarelli G, et al. Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteomics 2013; 125858: 1-15. [CrossRef] Yancik R, Ries LG, Yates JW. Ovarian cancer in the elderly: an analysis of surveillance, epidemiyology and end results program data. Am J Obstet Gynecol 1995; 154: 639. [CrossRef] Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol 2007; 25: 4159-61. [CrossRef] Kruse V, Cocquyt V, Borms M, Maes A, Van de Wiele C. Serum tumor markers and PET/CT imag- ing for tumor recurrence detection. Ann Nucl Med 2013; 27: 97-104. [CrossRef] Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-700.
  2. Moss EL, Moran A, Reynolds TM, Stokes-Lampard H. Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Womens Health 2013; 13: 8. [CrossRef] Mury D, Woelber L, Jung S, et al. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer. J Cancer Res Clin Oncol 2011; 137: 1131-7. [CrossRef] Wu L, Dai ZY, Qian YH, Shi Y, Liu